News

Video

Driven by Experience: How a Caregiver Became an MPN Advocate

Fact checked by:

An MPN advocate used his personal experiences to inform his dedication to patient-centered research and support programs for patients.

An advocate’s personal connection to cancer has shaped his approach to providing support to patients with myeloproliferative neoplasms (MPNs).

Richard Winneker, a patient advocate for the MPN Research Foundation, was nominated as an MPN Hero® for his vast experience in leading patient-centered research programs and focusing on patients with MPNs.

Winneker recalled his time as a caregiver to his son who had acute lymphoblastic leukemia as a child. He said that this experience has shaped his approach to research and the understanding of cancer’s impact on patients and families.

CURE sat down with Winneker ahead of the MPN Heroes event to learn about how his caregiver experience has formed how he advocates for patients with MPNs through research and beyond. For example, he recalls a pivotal moment in his work with the MPN Research Foundation, for which he helped with a patient-focused drug development meeting.

Transcript:

I'll start back with the fact that I had a son — I have a son who had acute lymphoblastic leukemia, so I brought the caregiver experience. I think just saying that word when your child has a cancer probably isn't enough to explain how traumatic it can be, and I've carried that with me through my entire research life.

But I would say the greatest impact that I've experienced during my time at the MPN Research Foundation was when we held, in 2019, an externally led, patient-focused drug development meeting. And that was a meeting where we brought together patients to really talk to representatives of the FDA and pharmaceutical companies about the burden of their disease, what their — what their concerns were and it really opened my eyes to — to how heterogeneous and how difficulty it can be living with these diseases.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of woman with black hair.
Image of man with black hair.
Image of woman with black hair.
Related Content